Guanabenz and methyldopa on hypertension and cardiac performance. 1977

B R Walker, and R S Shah, and K B Ramanathan, and S K Vanov, and R H Helfant

In previous placebo-controlled studies, guanabenz was shown to be a safe and effective antihypertensive drug without acute effects on cardiac function. In view of its therapeutic advantages, a double-blind comparison of guanabenz with methyldopa was performed in a group of 36 patients over 6 mo. Both drugs produced statistically and clinically significant decreases in blood pressure with similar side effects. No laboratory or electrocardiographic abnormalities were found other than positive Coombs' tests which developed in 3 patients during methyldopa therapy. Cardiac performance in 26 of the patients, as measured by noninvasive techniques, showed no significant changes from either drug except for a progressive and statistically significant increase in systolic time interval (QS2) and the ratio of the pre-ejection period to left ventricular ejection time (PEP/LVET) during methyldopa therapy. For an additional 6 mo, continued efficacy and safety were shown under open conditions in those patients who had received guanabenz. The study suggests that guanabenz may be an important new antihypertensive drug because of effectiveness, absence of adverse cardiac effects, and paucity of side effects.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008750 Methyldopa An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. Methyldopate,alpha-Methyldopa,Aldomet,Alphamethyldopa,Apo-Methyldopa,Dopamet,Dopegit,Dopegyt,Dopergit,Hydopa,Meldopa,Nu-Medopa,Sembrina,alpha-Methyl-L-Dopa,Apo Methyldopa,Nu Medopa,alpha Methyl L Dopa,alpha Methyldopa
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006143 Guanabenz An alpha-2 selective adrenergic agonist used as an antihypertensive agent. 2,6-Dichlorobenzylideneaminoguanidine,BR-750,Guanabenz Acetate,Guanabenz Monoacetate,WY-8678,Wyeth-Ayerst of Guanabenz Acetate,Wytensin,2,6 Dichlorobenzylideneaminoguanidine,Acetate Wyeth-Ayerst, Guanabenz,Acetate, Guanabenz,BR 750,BR750,Guanabenz Acetate Wyeth-Ayerst,Monoacetate, Guanabenz,WY 8678,WY8678,Wyeth Ayerst of Guanabenz Acetate
D006146 Guanidines A family of iminourea derivatives. The parent compound has been isolated from mushrooms, corn germ, rice hulls, mussels, earthworms, and turnip juice. Derivatives may have antiviral and antifungal properties.

Related Publications

B R Walker, and R S Shah, and K B Ramanathan, and S K Vanov, and R H Helfant
September 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
B R Walker, and R S Shah, and K B Ramanathan, and S K Vanov, and R H Helfant
January 1981, Clinical therapeutics,
B R Walker, and R S Shah, and K B Ramanathan, and S K Vanov, and R H Helfant
March 1979, Clinical pharmacology and therapeutics,
B R Walker, and R S Shah, and K B Ramanathan, and S K Vanov, and R H Helfant
March 1988, Revista medica de Chile,
B R Walker, and R S Shah, and K B Ramanathan, and S K Vanov, and R H Helfant
January 1984, Pediatric pharmacology (New York, N.Y.),
B R Walker, and R S Shah, and K B Ramanathan, and S K Vanov, and R H Helfant
March 1977, Clinical pharmacology and therapeutics,
B R Walker, and R S Shah, and K B Ramanathan, and S K Vanov, and R H Helfant
March 1963, British medical journal,
B R Walker, and R S Shah, and K B Ramanathan, and S K Vanov, and R H Helfant
August 1981, The Medical journal of Australia,
B R Walker, and R S Shah, and K B Ramanathan, and S K Vanov, and R H Helfant
January 1976, Farmakologiia i toksikologiia,
B R Walker, and R S Shah, and K B Ramanathan, and S K Vanov, and R H Helfant
January 1966, British medical journal,
Copied contents to your clipboard!